Key takeaways
- TA984 NICE recommended tafamidis for ATTR-CM on 19 June 2024, three years after rejecting it in TA696 (May 2021)
- TA1121 NICE's January 2026 acoramidis recommendation, directing clinicians to the least expensive suitable stabiliser
- TA868 / TA1115 Vutrisiran’s NICE recommendations for ATTR-PN (TA868, 2023, simple discount PAS) and ATTR-CM (TA1115, December 2025, commercial access agreement)
NICE rejected tafamidis in 2021 and recommended it in 2024. With acoramidis and vutrisiran now also recommended, UK ATTR-CM access turns on price, not on whether NICE will fund a stabiliser.
NICE's first appraisal of tafamidis (Vyndaqel/Vyndamax, Pfizer) for ATTR-CM, TA696 (May 2021), did not recommend it. The cost-effectiveness estimates were higher than what NICE normally considers an acceptable use of NHS resources, and there was not enough evidence that recommending tafamidis would reduce diagnosis delays, or about how long treatment works after it is stopped. Pfizer then initiated a review, submitting longer-term data from the ATTR-ACT extension study and a revised patient access scheme. NICE reviewed the decision and on 19 June 2024 published TA984, which recommends tafamidis within its marketing authorisation for wild-type or hereditary ATTR-CM in adults, provided the company supplies it under its commercial arrangement. The terms of that arrangement, a simple discount patient access scheme, are confidential.
Two further NICE decisions define the next phase of the UK ATTR market. Acoramidis (Beyonttra) was recommended under TA1121 (14 January 2026) on an indirect comparison with tafamidis, as no head-to-head trial exists, and NICE directed clinicians to use the least expensive suitable option, taking account of administration costs, dosages, price per dose and commercial arrangements. Vutrisiran (Amvuttra, Alnylam) was recommended for hereditary ATTR polyneuropathy under TA868 (15 February 2023) with a simple discount patient access scheme, and for ATTR-CM under TA1115 (December 2025) with a commercial access agreement.
UK ATTR amyloidosis agent NICE and NHS status
| Drug (Brand / INN) | NICE HTA Route | NICE Recommendation & PAS/MAA | NHS Commissioning Channel | Cost-Effectiveness Position | Key Payer Risk |
|---|---|---|---|---|---|
| Vyndaqel/Vyndamax (tafamidis) | Standard Technology Appraisal (TA696, 2021: not recommended; TA984, 2024: recommended) | Recommended with confidential PAS | NHS England Highly Specialised Cardiology — 25 centres | Recommended with a confidential commercial arrangement (TA984) | Acoramidis entry on indirect comparison; no head-to-head trial exists |
| Amvuttra (vutrisiran) | Standard Technology Appraisal (TA868, 2023; extended TA1115, 2025) | Recommended with confidential Patient Access Scheme | NHS England Highly Specialised Cardiology — ATTR-PN and ATTR-CM | Recommended for both ATTR-PN (TA868) and ATTR-CM (TA1115) indications | First NICE-recommended competitor to tafamidis in the ATTR-CM indication |
Sources: NICE TA696 (tafamidis, not recommended), May 2021; NICE TA984 (tafamidis, recommended), 19 June 2024; NICE TA868 (vutrisiran, ATTR-PN), 15 February 2023; NICE TA1115 (vutrisiran, ATTR-CM), December 2025; NICE TA1121 (acoramidis, ATTR-CM), 14 January 2026; NHS England ATTR-CM and ATTR-PN service commissioning documentation; ATTRibute-CM trial data (acoramidis), NEJM 2024.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why did NICE reject tafamidis in TA696 (2021) and recommend it in TA984 (2024), and what does that path mean for the next ATTR-CM appraisal? • TA696 committee reasons (cost-effectiveness above NICE's usual range • uncertainty on diagnosis delays and on benefit after stopping) • what changed by TA984 • how NHS commissioning follows TA984
- How will NICE evaluate acoramidis against tafamidis absent a head-to-head trial, and what incremental QALY gain must BridgeBio demonstrate to justify its WAC? • Indirect comparison methodology analysis (NT-proBNP, functional endpoints) • expected NICE appraisal timeline post-EMA approval • competitive positioning scenarios vs tafamidis at PAS-adjusted price
- What are the terms of vutrisiran’s NICE TA868 recommendation for ATTR-PN, and how does TA1115’s extension into ATTR-CM change the competitive picture against tafamidis? • TA868 Patient Access Scheme terms for ATTR-PN • TA1115 (December 2025) extension into ATTR-CM • competitive positioning against tafamidis now that vutrisiran has a NICE-recommended cardiomyopathy indication
What's inside
-
1 · UK ATTR Payer & Commissioning Landscape — NHS Highly Specialised Cardiology Overview 4 pp
- How NHS England Highly Specialised Cardiology services commission ATTR-CM care across 25 specialist centres following NICE's tafamidis recommendation
- Why NICE rejected tafamidis in May 2021 (TA696), and what the company brought to the review that became TA984
-
2 · NICE Tafamidis: From TA696 Rejection (2021) to TA984 Recommendation (2024) 6 pp
- How a confidential simple-discount patient access scheme took tafamidis from a negative to a positive NICE decision
- What Pfizer brought to the review that became TA984: longer-term ATTR-ACT extension data and a revised patient access scheme
-
3 · Acoramidis NICE Pipeline — Indirect Comparison & Competitive Positioning 5 pp
- Why acoramidis's NICE case rests on indirect NT-proBNP and functional-improvement comparisons against historical tafamidis data, with no head-to-head trial
- What incremental QALY gain BridgeBio must demonstrate to justify a WAC similar to tafamidis's once NICE appraisal begins post-EMA approval
-
4 · Vutrisiran NICE TA868/TA1115 — Patient Access Scheme & ATTR-CM Extension 5 pp
- TA868's February 2023 recommendation of vutrisiran for ATTR-PN under a straightforward Patient Access Scheme, not a Managed Access Agreement
- How TA1115's December 2025 extension into ATTR-CM gives tafamidis its first NICE-recommended head-to-head competitor in cardiomyopathy
-
5 · NHS ATTR Programme Budget — CM and PN Combined Spend Modelling 3 pp
- Why NHS spend on tafamidis cannot be read from public sources: its discount is confidential
- How vutrisiran's recommendation across both ATTR-PN (TA868) and ATTR-CM (TA1115) indications compounds the combined NHS ATTR programme budget
-
6 · Devolved Nations — Scotland (SMC) and Wales (AWMSG) Divergence Risk 3 pp
- How Scotland's SMC and Wales's AWMSG assess ATTR agents separately separately from NICE's TA984 and TA868 decisions, creating a divergence risk
- What a devolved-nation deviation from NICE's tafamidis and vutrisiran recommendations would mean for UK-wide access planning
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx ATTR Amyloidosis Payer & HTA is built for market access, HEOR, and pricing teams navigating tafamidis's path from NICE rejection (TA696) to recommendation (TA984), acoramidis's TA1121, vutrisiran’s TA868/TA1115 access route, and acoramidis’s pending NICE comparison in the UK. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (NICE TA, MAA, PAS), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, NICE appraisal analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NICE’s published Technology Appraisal documentation, NHS England Highly Specialised Cardiology commissioning specifications, and the ATTRibute-CM trial evidence behind acoramidis's NICE recommendation (TA1121).
Key sources: NICE TA696 (tafamidis, not recommended), May 2021; NICE TA984 (tafamidis, recommended), 19 June 2024; NICE TA868 (vutrisiran, ATTR-PN), 15 February 2023; NICE TA1115 (vutrisiran, ATTR-CM), December 2025; NICE TA1121 (acoramidis, ATTR-CM), 14 January 2026; NHS England ATTR-CM service commissioning and ATTR-PN registry specifications; ATTRibute-CM trial results, NEJM 2024. Devolved-nation positions (Scotland’s SMC, Wales’s AWMSG) are assessed separately from NICE's decisions.
- NICE TA696 (not recommended, May 2021) and TA984 (recommended with a commercial arrangement, 19 June 2024) checked against the NICE guidance pages
- NICE TA1121 (acoramidis, 14 January 2026) recommendation and its least-expensive-option direction checked against the NICE guidance page
- Vutrisiran’s Patient Access Scheme terms verified against the NICE TA868 Final Appraisal Determination, 2023, and the NICE TA1115 Final Appraisal Determination for ATTR-CM, 10 December 2025
- Acoramidis trial data verified against ATTRibute-CM published results, NEJM 2024, and the EMA acoramidis application timeline
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: the NICE tafamidis appraisal and its update, the NICE vutrisiran appraisals for polyneuropathy and for cardiomyopathy, and NHS England commissioning documentation. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.